(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Deadly attack on kindergarten reported in Sudan - 2I’m a dad to an autistic child. Here’s how you can make the holidays easier for all of us.
- 3The top astronomical discoveries of 2025
- 4Eli Lilly to build $6 billion Alabama plant as part of US manufacturing push
- 5Nurturing Hacks: Astuteness from Experienced Mothers and Fathers
- I'm a woman who's into weightlifting. Was I man enough for the creatine-packed 'Man Cereal'?
- Figure out How to Augment the Advantages of a Web-based Degree
- Moving Wedding Objections for Paramount Functions
- Must-See Attractions in Washington, D.C.
- ‘Nahariya get ready’: Banner displaying Hezbollah threat mounted in Tehran’s Palestine Square
- Discovery of ancient pleasure boat reveals Egypt's maritime history
- Astronaut on ISS captures spectacular orbital video of zodiacal light, auroras and the Pleiades
- One of the best meteor showers of the year peaks at the worst possible time this week
- Ancient fire discovery marks significant milestone in human history
